Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting
29 April 2021 - 11:00PM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB), a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer is pleased to
announce the acceptance of two poster presentations for DANYELZA
and an oral presentation for omburtamab at the American Society of
Clinical Oncology (“ASCO”) Virtual Annual Meeting, taking place
virtually from June 4, 2021 to June 8, 2021. The presentations were
submitted by Dr. Brian Kushner, Memorial Sloan Kettering Cancer
Center (“MSK”), Dr. Jaume Mora, M.D., Ph.D., SJD Barcelona
Children's Hospital and Dr. Mark Souweidane, MSK and Weill Cornell
Medicine:
DANYELZA (naxitamab-gqgk)
- Efficacy of naxitamab in patients
with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by
bone/bone marrow (BM) evaluation, potential sites of residual
disease (Dr. Kushner)
- Naxitamab and GM-CSF for
consolidation of High-Risk neuroblastoma (HR-NB) patients in
complete remission (Dr. Mora)
Omburtamab
- Phase 1 dose-escalation trial using
convection-enhanced delivery of 124I-omburtamab for diffuse
intrinsic pontine glioma following external radiation therapy (Dr.
Souweidane)
Researchers at MSK developed DANYELZA and
omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a
result of this licensing arrangement, MSK has institutional
financial interests in the products.
About Y-mAbsY-mAbs is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer. The Company has a
broad and advanced product pipeline, including one FDA approved
product, DANYELZA® (naxitamab-gqgk), which targets tumors that
express GD2, and one pivotal-stage product candidate, omburtamab,
which targets tumors that express B7-H3.
Forward-Looking
StatementsStatements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about our business model and
development, commercialization and product distribution plans;
current and future clinical and pre-clinical studies and our
research and development programs; expectations related to the
timing of the initiation and completion of regulatory submissions;
regulatory, marketing and reimbursement approvals; rate and degree
of market acceptance and clinical utility as well as pricing and
reimbursement levels; retaining and hiring key employees; our
commercialization, marketing and manufacturing capabilities and
strategy; our intellectual property position and strategy;
additional product candidates and technologies; collaborations or
strategic partnerships and the potential benefits thereof;
expectations related to the use of our cash and cash equivalents,
and the need for, timing and amount of any future financing
transaction; our financial performance, including our estimates
regarding revenues, expenses, capital expenditure requirements;
developments relating to our competitors and our industry; and
other statements that are not historical facts. Words such as
‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘should,’’ ‘‘targeted,’’ “will”, ‘‘would’’ and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. Our
product candidates and related technologies are novel approaches to
cancer treatment that present significant challenges. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including but not limited to: risks associated with our financial
condition and need for additional capital; risks associated with
our development work; cost and success of our product development
activities and clinical trials; the risks of delay in the timing of
our regulatory submissions or failure to receive approval of our
drug candidates; the risks related to commercializing any approved
pharmaceutical product including the rate and degree of market
acceptance of our product candidates; development of our sales and
marketing capabilities and risks associated with failure to obtain
sufficient reimbursement for our products; the risks related to our
dependence on third parties including for conduct of clinical
testing and product manufacture; our inability to enter into
partnerships; the risks related to government regulation; risks
related to market approval, risks associated with protection of our
intellectual property rights; risks related to employee matters and
managing growth; risks related to our common stock, risks
associated with the pandemic caused by the novel coronavirus known
as COVID-19 and other risks and uncertainties affecting the Company
including those described in the "Risk Factors" section included in
our Annual Report on Form 10-K for the year ended December 31,
2020, and in our other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and the Company undertakes no obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
“Y-mAbs®” and “DANYELZA®” are registered
trademarks of Y-mAbs Therapeutics, Inc.
Contact:
Y-mAbs
Therapeutics, Inc. 230 Park Avenue, Suite 3350New York, NY
10169USA +1 646 885 8505 E-mail: info@ymabs.com |
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024